Derivatives of dexanabinol. I. Water-soluble salts of glycinate esters

Pharmaceutical Research

Volumn 13, Issue 1, 1996, Pages 62-69

  Pop, Emil ^a   Liu, Zong Zheng ^a   Brewster, Marcus E ^a   Barenholz, Yechezkel ^b   Korablyov, Veronica ^b   Mechoulam, Raphael ^c   Nadler, Varda ^d   Biegon, Anat ^d  

^a Pharmos Corporation   (United States)

^b HEBREW UNIVERSITY   (Israel)

^c HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^d PHARMOS LTD   (Israel)

Author keywords

Cannabinoid; Dexanabinol; Glycinate; Prodrugs

Indexed keywords

CANNABINOID; CANNABINOID RECEPTOR; DEXANABINOL; DIZOCILPINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; PRODRUG;

ANIMAL CELL; ARTICLE; BRAIN INJURY; DOG; DRUG ACTIVITY; DRUG BINDING; DRUG STABILITY; DRUG SYNTHESIS; HUMAN; HYDROLYSIS; NEUROPROTECTION; PRIORITY JOURNAL; RAT;

ANIMALS; CELLS, CULTURED; DOGS; DRUG STABILITY; ESTERS; HUMANS; HYDROLYSIS; MOLECULAR STRUCTURE; NEUROPROTECTIVE AGENTS; PRODRUGS; RATS; RATS, SPRAGUE-DAWLEY; TETRAHYDROCANNABINOL; WATER;

EID: 0029868614     PISSN: 07248741     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1016025216390     Document Type: Article

References (29)

1. R. Mechoulam, N. Lander, A. Breuer, and J. Zahalka. Synthesis of the individual, pharmacologically distinct, enantiomers of a tetrahydrocannabinol derivative. Tetrahedron: Assymmetry, 1: 315-318 (1990).
2. R. Mechoulam, W.A. Devane, and R. Glaser. Cannabinoid geometry and biological activity. In "Marijuana/cannabinoids: neurobiology and neurophysiology". L. Murphy and A. Bartke (Ed.) CRC Press, Boca Raton, FL 1992, pp 1-33.
3. W.A. Devane, F.A. Dysarz III, M.R. Johnson, L.S. Melvin, and A.C. Howlett. Determination and characterization of a cannabinoid receptor in rat brain. Mol. Pharmacol., 34:605-613 (1988). For a review on the cannabinoid receptor, see: A.C. Howlett, M. Bidaut-Russell, W.A. Devane, L.S. Melvin, M.R. Johnson, and M. Herkenham. The cannabinoid receptor: biochemical, anatomical and behavioral characterization. Trends Neurosci. 13:420-423 (1990).
4. W.A. Devane, F.A. Dysarz III, M.R. Johnson, L.S. Melvin, and A.C. Howlett. Determination and characterization of a cannabinoid receptor in rat brain. Mol. Pharmacol., 34:605-613 (1988). For a review on the cannabinoid receptor, see: A.C. Howlett, M. Bidaut-Russell, W.A. Devane, L.S. Melvin, M.R. Johnson, and M. Herkenham. The cannabinoid receptor: biochemical, anatomical and behavioral characterization. Trends Neurosci. 13:420-423 (1990).
5. W.A. Devane, A. Breuer, T. Sheskin, T.U.C. Järbe, M.S. Eisen, and R. Mechoulam. A novel probe for the cannabinoid receptor. J. Med. Chem. 35:2065-2069 (1992).
6. a. N.E. Kaminski, M.E. Abood, F.K. Kesssler, B.R. Martin, and A.R. Schatz. Identification of a functionally relevant cannabinoid receptor on mouse spleen cells that is involved in cannabinoid-mediated immune modulation. Mol. Pharmacol., 42: 736-742 (1992).
7. b. S. Munro, K.L. Thomas, and M. Abu-Shaar. Molecular characterization of a peripheral receptor for cannabinoids. Nature, 365:61-65 (1993).
8. R. Mechoulam, J.J. Feigenbaum, N. Lander, M. Segal, T.U.C. Järbe, A.J. Hiltunen, and P. Consroe. Enantiomeric cannabinoids: Stereospecificity of psychotropic activity. Experientia, 44:762-764 (1988).
9. 8-THC-dimethylheptyl in mice and dogs. Pharmacol. Biochem. Behav., 32:661-666 (1989).
10. 9-THC and its relationship to pharmacological potency. J. Pharmacol. Exp. Ther., 255:624-630 (1990).
11. J.J. Feigenbaum, F. Bergmann, S.A. Richmond, R. Mechoulam, V. Nadler, Y. Kloog, and M. Sokolovsky. Nonpsychotropic cannabinoid acts as a functional N-methyl-D-aspartate receptor blocker. Proc. Natl. Acad. Sci. U.S.A., 86:9584-9587 (1989).
12. 8-tetrahydrocannabinol-dimethylheptyl to inhibit adenylate cyclase and bind to the cannabinoid receptor. Neuropharmacol., 29:161-165 (1990).
13. 8-tetrahydro-cannabinol in rats and pigeons. J. Pharmacol. Exp. Ther., 250:1000-1005 (1989).
14. J.J. Feigenbaum, S.E. Richmond, Y. Weissmann, and R. Mechoulam. Inhibition of cisplatin-induced emesis in the pigeon by a non-psychotropic synthetic cannabinoid. Eur. J. Pharmacol., 169:159-165 (1989).
15. R. Zeltser, Z. Seltzer, A. Eisen, J.J. Feigenbaum, and R. Mechoulam. Suppression of neuropathic pain behavior in rats by nonpsychotropic synthetic cannabinoid with NMDA receptor-blocking properties. Pain, 47:95-103 (1991).
16. N. Eshhar, S. Striem, and A. Biegon. HU-211, a nonpsychotropic cannabinoid, rescues cortical neurons from excitatory amino acid toxicity in culture. Neuro. Report, 5:237-240 (1993).
17. 2+ influx through the N-methyl-D-aspartate receptor on channel by the nonpsychotropic cannabinoid HU-211. Brain Res., 622:79-85 (1993).
18. 6-tetrahydrocannabinol 1,1-dimethylheptyl (HU-211) attenuates N-methyl-D-aspartate receptor mediated neurotoxicity in primary cultures rat forebrain. Neurosci. Let., 162:43-45 (1993).
19. E. Shohami, M. Novikov, and R. Mechoulam. A nonpsychotropic cannabinoid, HU-211, has cerebroprotective effects after closed head injury in the rat. J. Neurotrauma, 10:109-119 (1993).
20. A. Bar-Joseph, Y. Berkovitch, J. Adamchik, and A. Biegon. Neuroprotective activity of HU-211 a novel NMDA antagonist, in global ischemia in gerbils. Molecular and Chemical Neuropathology, 23:125-135 (1994).
21. E. Shohami, M. Novikov, and R. Bass. Long term effects of HU-211, a novel noncompetitive NMDA antagonist, on motor and memory functions after closed head injury in the rat. Brain Res., in press.
22. H. Bundgaard. Design of prodrugs: bioreversible derivatives for various functional groups and chemical entities. In Design of Prodrugs; Bundgaard, H. Ed.; Elsevier: New York, 1985; pp 1-92.
23. A. Sinkula, and S. Yalkowsky. Rationale for design of biologically reversible drug derivatives: Prodrugs. J. Pharm. Sci., 64: 181-210 (1975).
24. V. Stella. Prodrugs: An overview and definition. In Prodrugs as Novel Drug Delivery Systems; Higuchi, T., Stella, V., Eds.; American Chemical Society: Washington, DC, 1975; pp 1-115.
25. J.Y. Koh, and D.W. Choi. Quantitative determination of glutamate mediated cortical neuronal injury in cell culture by lactate dehydrogenase efflux assay. J. Neurosci. Methods, 20:83-90 (1987).
26. P.J. Munson, and D. Rodbard. LIGAND: a vrsatile computerized approach for characterization of ligand-binding systems, Anal. Biochem., 107:220-239 (1980).
27. E. Pop, M-J. Huang N. Bodor, and M.E. Brewster. Hydrolytic stability of allylic and phenolic esters of some synthetic cannabinoids; a theoretical (AM1) study. Int. J. Quantum Chem.; Quantum Biol. Symposium, 22:137-143 (1995).
28. K-B. Augustinsson. Multiple forms of esterase in vertebrate blood plasma. Ann. N.Y. Acad. Sci., 94;, 844-860 (1961).
29. E. Pop. Targeting penicillins to the central nervous system: chemical delivery systems and redox analogs. Advanced Drug Delivery Rev., 14:211-226 (1994).